Pulmonary hypertension in chronic lung disease and hypoxia
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Pulmonary hypertension (PH) frequently complicates the course of patients with various forms of chronic lung disease (CLD). CLD-associated PH (CLD-PH) is invariably associated with reduced functional ability, impaired quality of life, greater oxygen requirements and an increased risk of mortality. The aetiology of CLD-PH is complex and multifactorial, with differences in the pathogenic sequelae between the diverse forms of CLD. Haemodynamic evaluation of PH severity should be contextualised within the extent of the underlying lung disease, which is best gauged through a combination of physiological and imaging assessment. Who, when, if and how to screen for PH will be addressed in this article, as will the current state of knowledge with regard to the role of treatment with pulmonary vasoactive agents. Although such therapy cannot be endorsed given the current state of findings, future studies in this area are strongly encouraged.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The OPTN/UNOS registry data demonstrate that Group 3 pulmonary hypertension is common in patients with advanced CF, ILD, and COPD and is associated with increased oxygen requirements and increased mortality.(294–299)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [294]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis
Lettieri, C. J., Nathan, S. D., Barnett, S. D., Ahmad, S., & Shorr, A. F. (2006) · Chest · doi:10.1378/chest.129.3.746 · Cited by 879
Self-citationSildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
Ghofrani, H. A., Wiedemann, R., Rose, F., Schermuly, R. T., Olschewski, H., Weissmann, N., Gunther, A., Walmrath, D., Seeger, W., & Grimminger, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11024-5 · Cited by 769
Self-citationSevere Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
Chaouat, A., Bugnet, A.-S., Kadaoui, N., Schott, R., Enache, I., Ducoloné, A., Ehrhart, M., Kessler, R., & Weitzenblum, E. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200401-006oc · Cited by 714
Pulmonary Hypertension in Chronic Lung Diseases
Seeger, W., Adir, Y., Barberà, J. A., Champion, H., Coghlan, J. G., Cottin, V., De Marco, T., Galiè, N., Ghio, S., Gibbs, S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.036 · Cited by 673
Self-citationA Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002110 · Cited by 634
Consensus Statement on Chronic and Subacute High Altitude Diseases
León-Velarde, F., Maggiorini, M., Reeves, J. T., Aldashev, A., Asmus, I., Bernardi, L., Ge, R.-L., Hackett, P., Kobayashi, T., Moore, L. G., et al. (2005) · High Altitude Medicine & Biology · doi:10.1089/ham.2005.6.147 · Cited by 630
Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial
Raghu, G., Behr, J., Brown, K. K., Egan, J. J., Kawut, S. M., Flaherty, K. R., Martinez, F. J., Nathan, S. D., Wells, A. U., Collard, H. R., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-9-201305070-00003 · Cited by 553
Self-citationKESSLER, R., FALLER, M., FOURGAUT, G., MENNECIER, B., & WEITZENBLUM, E. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.1.9803117 · Cited by 549
Obesity-Associated hypoventilation in hospitalized patients: prevalence, effects, and outcome
Nowbar, S., Burkart, K. M., Gonzales, R., Fedorowicz, A., Gozansky, W. S., Gaudio, J. C., Taylor, M. R. G., & Zwillich, C. W. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.022 · Cited by 512
Clinical features of paediatric pulmonary hypertension: a registry study
Berger, R. M., Beghetti, M., Humpl, T., Raskob, G. E., Ivy, D. D., Jing, Z.-C., Bonnet, D., Schulze-Neick, I., & Barst, R. J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61621-8 · Cited by 508
Cited by
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 3,975
Self-citationHaemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00879-2022 · Cited by 2,247
Self-citationLeard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
An overview of the 6th World Symposium on Pulmonary Hypertension
Galiè, N., McLaughlin, V. V., Rubin, L. J., & Simonneau, G. (2019) · European Respiratory Journal · doi:10.1183/13993003.02148-2018 · Cited by 526
Diagnosis of pulmonary hypertension
Frost, A., Badesch, D., Gibbs, J. S. R., Gopalan, D., Khanna, D., Manes, A., Oudiz, R., Satoh, T., Torres, F., & Torbicki, A. (2019) · European Respiratory Journal · doi:10.1183/13993003.01904-2018 · Cited by 479
Pulmonary Hypertension: A Brief Guide for Clinicians
Mandras, S. A., Mehta, H. S., & Vaidya, A. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.04.039 · Cited by 271
Nathan, S. D., Behr, J., Collard, H. R., Cottin, V., Hoeper, M. M., Martinez, F. J., Corte, T. J., Keogh, A. M., Leuchte, H., Mogulkoc, N., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30250-4 · Cited by 253
Self-citationTreatment algorithm for pulmonary arterial hypertension
Chin, K. M., Gaine, S. P., Gerges, C., Jing, Z.-C., Mathai, S. C., Tamura, Y., McLaughlin, V. V., & Sitbon, O. (2024) · European Respiratory Journal · doi:10.1183/13993003.01325-2024 · Cited by 252
Self-citationMiravitlles, M., Rubio, M. C., Molina, J., Almagro, P., Gómez, J.-T., Trigueros, J. A., Cosío, B. G., Casanova, C., López-Campos, J. L., Riesco, J. A., et al. (2021) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2021.03.005 · Cited by 241
Cottin, V., Selman, M., Inoue, Y., Wong, A. W., Corte, T. J., Flaherty, K. R., Han, M. K., Jacob, J., Johannson, K. A., Kitaichi, M., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202206-1041st · Cited by 226
Therapeutic Properties and Pharmacological Activities of Asiaticoside and Madecassoside: A Review
Bandopadhyay, S., Mandal, S., Ghorai, M., Jha, N. K., Kumar, M., Radha, Ghosh, A., Proćków, J., Pérez de la Lastra, J. M., & Dey, A. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17635 · Cited by 220
The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure
Boucherat, O., Agrawal, V., Lawrie, A., & Bonnet, S. (2022) · Circulation Research · doi:10.1161/circresaha.121.319971 · Cited by 196
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis
Hoeper, M. M., Dwivedi, K., Pausch, C., Lewis, R. A., Olsson, K. M., Huscher, D., Pittrow, D., Grünig, E., Staehler, G., Vizza, C. D., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00097-2 · Cited by 191
Self-citationThe superoxide radical switch in the biology of nitric oxide and peroxynitrite
Piacenza, L., Zeida, A., Trujillo, M., & Radi, R. (2022) · Physiological Reviews · doi:10.1152/physrev.00005.2022 · Cited by 190
Poch, D., & Mandel, J. (2021) · Annals of Internal Medicine · doi:10.7326/aitc202104200 · Cited by 187
Pulmonary hypertension associated with lung diseases
Shlobin, O. A., Adir, Y., Barberà, J. A., Cottin, V., Harari, S. A., Jutant, E., Pepke‐Żaba, J., Ghofrani, H. A., & Channick, R. N. (2024) · European Respiratory Journal · doi:10.1183/13993003.01200-2024 · Cited by 179
Self-citationOlsson, K. M., Corte, T. J., Kamp, J. C., Montani, D., Nathan, S. D., Neubert, L., Price, L. C., & Kiely, D. G. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00259-x · Cited by 168
Self-citationSleep-related breathing disorders and pulmonary hypertension
Adir, Y., Humbert, M. J. C., & Chaouat, A. (2020) · European Respiratory Journal · doi:10.1183/13993003.02258-2020 · Cited by 167
Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension
Boucly, A., Cottin, V., Nunes, H., Jaïs, X., Tazi, A., Prévôt, G., Reynaud-Gaubert, M., Dromer, C., Viacroze, C., Horeau-Langlard, D., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00465-2017 · Cited by 156
Treatment of pulmonary arterial hypertension: recent progress and a look to the future
Humbert, M. J. C., Sitbon, O., Guignabert, C., Savale, L., Boucly, A., Gallant-Dewavrin, M., McLaughlin, V. V., Hoeper, M. M., & Weatherald, J. C. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00264-3 · Cited by 159
Rajagopal, S., Ruetzler, K., Ghadimi, K., Horn, E. M., Kelava, M., Kudelko, K. T., Moreno‐Duarte, I., Preston, I. R., Bovino, L. R., Smilowitz, N. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001136 · Cited by 149
Pulmonary Hypertension in Patients With COPD
Vizza, C. D., Hoeper, M. M., Huscher, D., Pittrow, D., Benjamin, N., Olsson, K. M., Ghofrani, H. A., Held, M., Klose, H. F. E., Lange, T. J., et al. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.02.012 · Cited by 141
Self-citationComorbidities in idiopathic pulmonary fibrosis: an underestimated issue
Caminati, A., Lonati, C., Cassandro, R., Elia, D., Pelosi, G., Torre, O., Zompatori, M., Uslenghi, E., & Harari, S. A. (2019) · European Respiratory Review · doi:10.1183/16000617.0044-2019 · Cited by 139
Self-citationImaging of pulmonary hypertension in adults: a position paper from the Fleischner Society
Rémy‐Jardin, M., Ryerson, C. J., Schiebler, M. L., Leung, A. N. C., Wild, J. M., Hoeper, M. M., Alderson, P. O., Goodman, L. R., Mayo, J. R., Haramati, L. B., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04455-2020 · Cited by 136
Olsson, K. M., Hoeper, M. M., Pausch, C., Grünig, E., Huscher, D., Pittrow, D., Rosenkranz, S., & Gall, H. J. (2021) · European Respiratory Journal · doi:10.1183/13993003.01483-2021 · Cited by 129
Self-citationEvaluation and management of pulmonary arterial hypertension
Beshay, S. M., Sahay, S., & Humbert, M. J. C. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106099 · Cited by 123
Crnković, S., Valzano, F., Fließer, E., Gindlhuber, J., Puthenparampil, H. T., Basil, M. C., Morley, M. P., Katzen, J. B., Gschwandtner, E., Klepetko, W., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153471 · Cited by 123
Self-citationElevated pulmonary vascular resistance predicts mortality in COPD patients
Zeder, K., Avian, A., Bachmaier, G., Douschan, P., Foris, V., Sassmann, T., Troester, N., Brčić, L., Fuchsjäger, M., Marsh, L. M., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.00944-2021 · Cited by 122
Self-citationSevere Pulmonary Hypertension in COPD
Kovács, G., Avian, A., Bachmaier, G., Troester, N., Tornyos, A., Douschan, P., Foris, V., Sassmann, T., Zeder, K., Lindenmann, J., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.01.031 · Cited by 120
Self-citationUpdated Perspectives on Pulmonary Hypertension in COPD
Blanco, I., Tura-Ceide, O., Peinado, V. I., & Barberà, J. A. (2020) · International Journal of COPD · doi:10.2147/copd.s211841 · Cited by 115
Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner Society
Rémy‐Jardin, M., Ryerson, C. J., Schiebler, M. L., Leung, A. N. C., Wild, J. M., Hoeper, M. M., Alderson, P. O., Goodman, L. R., Mayo, J. R., Haramati, L. B., et al. (2021) · Radiology · doi:10.1148/radiol.2020203108 · Cited by 115
Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis
May, J. M., Mitchell, J. A., & Jenkins, G. R. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172058 · Cited by 115
Pulmonary hypertension in chronic obstructive pulmonary disease
Gredic, M., Blanco, I., Kovács, G., Helyes, Z., Ferdinandy, P., Olschewski, H., Barberà, J. A., & Weißmann, N. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14979 · Cited by 113
Self-citationOSA and Chronic Respiratory Disease: Mechanisms and Epidemiology
Locke, B. W., Lee, J. J., & Sundar, K. M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19095473 · Cited by 113
Lung transplantation for interstitial lung disease
Kapnadak, S. G., & Raghu, G. (2021) · European Respiratory Review · doi:10.1183/16000617.0017-2021 · Cited by 91
Karnati, S., Seimetz, M., Kleefeldt, F., Sonawane, A., Madhusudhan, T., Bachhuka, A., Kosanovic, D., Weißmann, N., Krüger, K., & Ergün, S. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.649512 · Cited by 109
Canepa, M., Franssen, F. M. E., Olschewski, H., Lainščak, M., Böhm, M., Tavazzi, L., & Rosenkranz, S. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.05.009 · Cited by 108
Self-citationThe Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease
King, C. S., & Shlobin, O. A. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.04.046 · Cited by 107
Ruffenach, G., Hong, J. S., Vaillancourt, M., Medzikovic, L., & Eghbali, M. (2020) · Respiratory Research · doi:10.1186/s12931-020-01570-2 · Cited by 104
The vascular perspective on acute and chronic lung disease
Borek, I., Birnhuber, A., Voelkel, N. F., Marsh, L. M., & Kwapiszewska, G. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170502 · Cited by 103
ALDH2 (Aldehyde Dehydrogenase 2) Protects Against Hypoxia-Induced Pulmonary Hypertension
Zhao, Y., Wang, B., Zhang, J., He, D., Zhang, Q., Pan, C., Yuan, Q., Shi, Y., Tang, H., Xu, F., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312946 · Cited by 101
Tobal, R., Potjewijd, J., van Empel, V. P. M., Ysermans, R., Schurgers, L. J., Reutelingsperger, C. P. M., Damoiseaux, J. G. M. C., & van Paassen, P. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.806899 · Cited by 99
Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update
Coons, J. C., Pogue, K. T., Kolodziej, A., Hirsch, G. A., & George, M. P. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1235-4 · Cited by 98
Group 3 Pulmonary Hypertension: From Bench to Bedside
Singh, N., Dorfmüller, P., Shlobin, O. A., & Ventetuolo, C. E. (2022) · Circulation Research · doi:10.1161/circresaha.121.319970 · Cited by 98
Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary
Lu, W., Aarsand, R., Schotte, K., Han, J., Lebedeva, E., Tsoy, E., Maglakelidze, N., Soriano, J. B., Bill, W., Halpin, D. M. G., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-02961-5 · Cited by 97
Lewis, R. A., Thompson, A. A. R., Billings, C., Charalampopoulos, A. F., Elliot, C. A., Hamilton, N., Hill, C., Hurdman, J. A., Rajaram, S., Sabroe, I., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00041-2020 · Cited by 96
Pulmonary Hypertension Definition, Classification, and Epidemiology in Asia
Anderson, J., & Lau, E. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.04.008 · Cited by 94
Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease
Rahaghi, F., Kolaitis, N. A., Adegunsoye, A., de Andrade, J. A., Flaherty, K. R., LANCASTER, L. H., Lee, J. S., Levine, D. J., Preston, I. R., Safdar, Z., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.02.012 · Cited by 90
Self-citationCardiovascular disease in chronic obstructive pulmonary disease: a narrative review
Balbirsingh, V., Mohammed, A. S., Turner, A. M., & Newnham, M. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-218333 · Cited by 89
Kopeć, G., Kurzyna, M., Mroczek, E., Chrzanowski, Ł., Mularek‐Kubzdela, T., Skoczylas, I., Kuśmierczyk, B., Pruszczyk, P., Błaszczak, P., Lewicka, E., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010173 · Cited by 88
Frataxin deficiency promotes endothelial senescence in pulmonary hypertension
Culley, M. K., Zhao, J., Tai, Y., Tang, Y., Perk, D., Negi, V., Yu, Q., Woodcock, C.-S. C., Handen, A. L., Speyer, G., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci136459 · Cited by 87
Guidelines for the Treatment of Pulmonary Arterial Hypertension
Vazquez, Z. G. S., & Klinger, J. R. (2020) · Lung · doi:10.1007/s00408-020-00375-w · Cited by 86
Waxman, A. B., Restrepo‐Jaramillo, R., Thenappan, T., Engel, P. A., Bajwa, A. A., Ravichandran, A. K., Feldman, J., Case, A. H., Argula, R. G., Tapson, V. F., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.02414-2022 · Cited by 86
Self-citationShi, Y., Liu, J., Zhang, R., Zhang, M., Cui, H., Wang, L., Cui, Y., Wang, W., Sun, Y., & Wang, C. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.19857 · Cited by 85
Avdeev, S. N., Барбараш, О. Л., Солтановна, В. З., Volkov, A. V., Veselova, T. N., Galyavich, A. S., Goncharova, N. S., Gorbachevsky, S. V., Владимирович, Г. В., Danilov, N. M., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6161 · Cited by 85
Nathan, S. D., Tapson, V. F., Elwing, J., Rischard, F. P., Mehta, J. P., Shapiro, S., Shen, E., Deng, C., Smith, P., & Waxman, A. B. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202107-1766oc · Cited by 82
Self-citationTello, K., Ghofrani, H. A., Heinze, C., Krueger, K., Naeije, R., Raubach, C., Seeger, W., Sommer, N., Gall, H. J., & Richter, M. J. (2019) · European Respiratory Journal · doi:10.1183/13993003.02435-2018 · Cited by 79
Self-citationManagement of Pulmonary Arterial Hypertension
Mayeux, J. D., Pan, I. Z., Dechand, J., Jacobs, J. A., Jones, T. L., McKellar, S. H., Beck, E. M., Hatton, N. D., & Ryan, J. J. (2020) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-020-00663-3 · Cited by 79
Hipertensión arterial pulmonar
Luna‐López, R., Martín, A. R., & Subías, P. E. (2022) · Medicina Clínica · doi:10.1016/j.medcli.2022.01.003 · Cited by 72
Nikkho, S. M., Richter, M. J., Shen, E., Abman, S. H., Antoniou, K., Chung, J. H., Fernandes, P., Hassoun, P. M., Lazarus, H. M., Olschewski, H., et al. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12127 · Cited by 72
Self-citationWASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension
Savale, L., Huitema, M. P., Shlobin, O. A., Kouranos, V., Nathan, S. D., Nunes, H., Gupta, R., Grutters, J. C., Culver, D. A., Post, M. C., et al. (2022) · European Respiratory Review · doi:10.1183/16000617.0165-2021 · Cited by 71
Self-citationRecent advances in the management of pulmonary hypertension with interstitial lung disease
Waxman, A. B., Elia, D., Adir, Y., Humbert, M. J. C., & Harari, S. A. (2022) · European Respiratory Review · doi:10.1183/16000617.0220-2021 · Cited by 71
Self-citationThe new haemodynamic definition of pulmonary hypertension: evidence prevails, finally!
Hoeper, M. M., & Humbert, M. J. C. (2019) · European Respiratory Journal · doi:10.1183/13993003.00038-2019 · Cited by 69
The Effect of Borderline Pulmonary Hypertension on Survival in Chronic Lung Disease
Piccari, L., Wort, S. J., Meloni, F., Rizzo, M., Price, L. C., Martino, L., Salvaterra, E., Scelsi, L., López‐Meseguer, M., Blanco, I., et al. (2022) · Respiration · doi:10.1159/000524263 · Cited by 68
Pathobiology of pulmonary artery hypertension: role of long non-coding RNAs
Zahid, K. R., Raza, U., Chen, J., Raj, U. J., & Gou, D. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa050 · Cited by 66
Thomas, C. A., Anderson, R. J., Condon, D. F., & Pérez, V. D. J. (2019) · Pulmonary Therapy · doi:10.1007/s41030-019-00105-5 · Cited by 65
Contemporary Treatment of Pulmonary Arterial Hypertension: A U.S. Perspective
Sahay, S., Chakinala, M. M., Kim, N. H., Preston, I. R., Thenappan, T., & McLaughlin, V. V. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202405-0914so · Cited by 64
Lung transplantation for sarcoidosis: outcome and prognostic factors
Pavec, J. L., Valeyre, D., Gazengel, P., Holm, A. M., Schultz, H. H. L., Perch, M., Borgne, A. L., Reynaud‐Gaubert, M., Knoop, C., Godinas, L., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.03358-2020 · Cited by 64
Self-citationTreatment of severe stable COPD: the multidimensional approach of treatable traits
van Dijk, M., Gan, C. T., Koster, T. D., Wijkstra, P. J., Slebos, D., Kerstjens, H. A. M., van der Vaart, H., & Duiverman, M. L. (2020) · ERJ Open Research · doi:10.1183/23120541.00322-2019 · Cited by 61
Avdeev, S. N., Барбараш, О. Л., Баутин, А. Е., Volkov, A. V., Veselova, T. N., Galyavich, A. S., Goncharova, N. S., Gorbachevsky, S. V., Danilov, N. M., Еременко, А. А., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4683 · Cited by 61
Świetlik, E. M., Greene, D., Zhu, N., Mégy, K., Cogliano, M., Rajaram, S., Pandya, D., Tilly, T., Lutz, K. A., Welch, C. L., et al. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003155 · Cited by 61
Self-citationEvaluation and classification of pulmonary arterial hypertension
Sahay, S. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.54 · Cited by 60
Dauriat, G., Reynaud‐Gaubert, M., Cottin, V., Lamia, B., Montani, D., Canuet, M., Boissin, C., Tromeur, C., Chaouat, A., Degano, B., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.021 · Cited by 59
Phenotypes in pulmonary hypertension
Weatherald, J. C., Hemnes, A. R., Maron, B. A., Mielniczuk, L. M., Gerges, C., Price, L. C., Hoeper, M. M., & Humbert, M. J. C. (2024) · European Respiratory Journal · doi:10.1183/13993003.01633-2023 · Cited by 58
Tang, W. H. W., Wilcox, J. D., Jacob, M. S., Rosenzweig, E. B., Borlaug, B. A., Frantz, R. P., Hassoun, P. M., Hemnes, A. R., Hill, N. S., Horn, E. M., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.006363 · Cited by 58
Yogeswaran, A., Kuhnert, S., Gall, H. J., Faber, M., Krauss, E., Rako, Z. A., Keranov, S., Grimminger, F., Ghofrani, H. A., Naeije, R., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.826369 · Cited by 57
Self-citationPulmonary hypertension in patients with interstitial lung disease: a tool for early detection
Parikh, R., Konstantinidis, I., O’Sullivan, D. M., & Farber, H. W. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12141 · Cited by 55
Piccari, L., Allwood, B., Antoniou, K., Chung, J. H., Hassoun, P. M., Nikkho, S. M., Saggar, R., Shlobin, O. A., Vitulo, P., Nathan, S. D., et al. (2023) · Pulmonary Circulation · doi:10.1002/pul2.12213 · Cited by 54
Self-citationCardiovascular Risk in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review
Sá‐Sousa, A., Rodrigues, C., Jácome, C. I. O., Cardoso, J., Fortuna, I., Guimarães, M., Pinto, P., Sarmento, P., & Baptista, R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175173 · Cited by 54
Predictors of Mortality in Patients with Interstitial Lung Disease-Associated Pulmonary Hypertension
Alhamad, E. H., Cal, J. G., Alrajhi, N. N., & Alharbi, W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123828 · Cited by 52
Atualização no Tratamento da Hipertensão Arterial Pulmonar
Fernandes, C. J. C. D. S., Calderaro, D., Assad, A. P. L., Salibe-Filho, W., Morinaga, L. T. K., Hoette, S., Piloto, B. M., Castro, M. A., Lisboa, R. P., da Silva, T. A. F., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20200702 · Cited by 52
Karia, N., Howard, L., Johnson, M., Kiely, D. G., Lordan, J. L., McCabe, C., Pepke‐Żaba, J., Ong, R. C.-Y., Preiß, M., Knight, D. S., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad532 · Cited by 51
Pulmonary Hypertension Associated with Connective Tissue Disease
Fayed, H., & Coghlan, G. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1685214 · Cited by 51
Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra
Rajagopal, K., Bryant, A. J., Sahay, S., Wareing, N. E., Zhou, Y., Pandit, L. M., & Karmouty‐Quintana, H. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15036 · Cited by 51
Pulmonary hypertension in interstitial lung disease: an area of unmet clinical need
Dhont, S., Zwaenepoel, B. A. C., Vandecasteele, E. H., Brusselle, G., & Pauw, M. D. (2022) · ERJ Open Research · doi:10.1183/23120541.00272-2022 · Cited by 48
Sakao, S. (2019) · Respiratory Investigation · doi:10.1016/j.resinv.2019.03.013 · Cited by 47
Miravitlles, M., Calle, M., Molina, J., Almagro, P., Gómez, J.-T., Trigueros, J. A., Cosío, B. G., Casanova, C., López-Campos, J. L., Riesco, J. A., et al. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2021.03.026 · Cited by 47
Tanabe, N., Kumamaru, H., Tamura, Y., Taniguchi, H., Emoto, N., Yamada, Y., Nishiyama, O., Tsujino, I., Kuraishi, H., Nishimura, Y., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-0939 · Cited by 45
Lung Diseases in Inflammatory Myopathies
Barba, T., Mainbourg, S., Nasser, M., Lega, J., & Cottin, V. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1685187 · Cited by 45
Nikitopoulou, I., Manitsopoulos, N., Kotanidou, A., Tian, X., Petrovic, A., Magkou, C., Ninou, I., Aidinis, V., Schermuly, R. T., Kosanovic, D., et al. (2019) · Pulmonary Circulation · doi:10.1177/2045894019881954 · Cited by 44
Pulmonary vascular disease and pulmonary hypertension
Ghigna, M., & Dorfmüller, P. (2019) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2019.05.002 · Cited by 44
van Heerden, J. K., Louw, E. H., Thienemann, F., Engel, M. E., & Allwood, B. (2024) · European Respiratory Review · doi:10.1183/16000617.0154-2023 · Cited by 44
DuBroff, J. J., Melendres-Groves, L. D., Lin, Y., Beene, D., & Ketai, L. H. (2019) · Pulmonary Circulation · doi:10.1177/2045894019894534 · Cited by 44
NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD
Seimetz, M., Sommer, N., Bednorz, M., Pak, O., Veith, C., Hadžić, S., Gredic, M., Parajuli, N., Kojonazarov, B. K., Kraut, S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0215-8 · Cited by 44
Self-citationTreatment of pulmonary hypertension associated with COPD: a systematic review
Arif, R., Pandey, A. K., Zhao, Y., Arsenault‐Mehta, K., Khoujah, D., & Mehta, S. (2021) · ERJ Open Research · doi:10.1183/23120541.00348-2021 · Cited by 44
Nathan, S. D., Deng, C., King, C. S., DuBrock, H. M., Elwing, J., Rajagopal, S., Rischard, F. P., Sahay, S., Broderick, M. J., Shen, E., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.09.007 · Cited by 44
Self-citationPericytes: The lung-forgotten cell type
Garrison, A. T., Bignold, R. E., Wu, X., & Johnson, J. R. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1150028 · Cited by 44
Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases
Kawamatawong, T. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.518345 · Cited by 42
Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD
Miravitlles, M., Rubio, M. C., Molina, J., Almagro, P., Gómez, J.-T., Trigueros, J. A., Cosío, B. G., Casanova, C., López-Campos, J. L., Riesco, J. A., et al. (2021) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2021.03.014 · Cited by 42
Metadata
- Authors
- Nathan, S. D., Barbera, J. A., Gaine, S. P., Harari, S., Martinez, F. J., Olschewski, H., Olsson, K. M., Peacock, A. J., Pepke-Zaba, J., Provencher, S., Weissmann, N., & Seeger, W.
- Affiliations
- Inova Fairfax Hospital (US)
- MultiMedica (IT)
- Medical University of Graz (AT)
- Medizinische Hochschule Hannover (DE)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Justus-Liebig-Universität Gießen (DE)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2019-01
- Volume
- 53
- Issue
- 1
- Pages
- 1801914
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC6351338
- OpenAlex
- W2904463477
- Cited by
- 757
- References
- 94
- Citations by year
- 2026: 54 · 2025: 104 · 2024: 141 · 2023: 96 · 2022: 122 · 2021: 114 · 2020: 76 · 2019: 44
- FWCI
- 10.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- European Respiratory Journal (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by-nc)
- Funders
- American Thoracic Society
- Pfizer
- AstraZeneca
- Bayer
- GlaxoSmithKline
- Gilead Sciences
- Biogen
- Teva Pharmaceutical Industries
- United Therapeutics Corporation
- Sunovion
- Veracyte
- York University
- National Institutes of Health
- Genentech
- Actelion Pharmaceuticals
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- pulmonary hypertension, chronic lung disease, hypoxia, hemodynamic assessment, quality of life, mortality risk, oxygen requirement
- MeSH terms
- Animals, Hypoxia, Antihypertensive Agents, Chronic Disease, Humans, Hypertension, Pulmonary, Lung Diseases, Interstitial, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.